• by Paul Armentano, NORML Deputy Director March 5, 2018

    Pain reliefCannabis therapy mitigates symptoms of the chronic pain condition fibromyalgia and is associated with a reduction in the use of other prescription drugs, according to clinical data published online ahead of print in the Journal of Clinical Rheumatology. An estimated 3 to 6 million Americans are afflicted by fibromyalgia, which is often poorly controlled by standard pain medications.

    Israeli investigators assessed the safety and efficacy of inhaled cannabis in a cohort of 26 patients with fibromyalgia. They reported that medical cannabis treatment “was associated with significant favorable outcomes in every item evaluated,” such as reductions in pain and increases in energy.

    Most patients also reduced their use of conventional prescription drugs, such as opiates and benzodiazepines, during the trial period. Nearly half of the participants (46 percent) reduced their prescription drug intake by more than 50 percent during the study. Several patients were also able to return to work following the initiation of cannabis therapy.

    Researchers concluded, “Medical cannabis treatment had a significant favorable effect on patients with fibromyalgia, with few adverse effects.”

    Prior trials evaluating the use of either whole-plant cannabis or synthetic cannabinoids have similarly shown efficacy in patients with the disease. A summary of these prior studies is available here.

    The abstract of the study, “Medical cannabis for the treatment of fibromyalgia,” is online here.

  • by Paul Armentano, NORML Deputy Director March 1, 2018

    Patients routinely reduce or eliminate their use of prescription opiates following the use of medical cannabis; two recently published studies reaffirm this relationship.

    In the first study, published by the Minnesota Department of Health, investigators assessed the prescription drug use patterns of 2,245 intractable pain patients participating in the state’s medical cannabis access program. Among those patients known to be taking opiates for pain upon enrollment in the program, 63 percent “were able to reduce or eliminate opioid usage after six months.” The findings are similar to those of registered patients in other states’ medical cannabis programs, including Illinois, Michigan, and New Mexico, among others.

    In the second study, Israeli researchers assessed the safety and efficacy of cannabis in a cohort of over 1,200 cancer patients over a period of six months. Ninety-six percent of patients “reported an improvement in their condition.” Nearly half of respondents reported either decreasing or eliminating their use of opioids during the treatment period.

    A third recently published clinical trial provides insight into explaining this relationship. Investigators from the United States and Australia and assessed the efficacy of inhaled cannabis and sub-therapeutic doses of oxycodone on experimentally-induced pain in a double-blind, placebo-controlled model. Researchers assessed subjects’ pain tolerance after receiving both substances separately or in concert with one another. While neither the administration of cannabis nor oxycodone alone significantly mitigated subjects’ pain, the combined administration of both drugs did so effectively.

    Authors determined, “Both active cannabis and a low dose of oxycodone (2.5 mg) were sub-therapeutic, failing to elicit analgesia on their own; however, when administered together, pain responses … were significantly reduced, pointing to the opioid-sparing effects of cannabis.” They concluded, “Smoked cannabis combined with an ineffective analgesic dose of oxycodone produced analgesia comparable to an effective opioid analgesic dose without significantly increasing cannabis’s abuse liability.”

    The new studies add to the growing body of research finding that cannabis access is associated with reduced rates of opioid use and abuse, opioid-related hospitalizations, opioid-related traffic fatalities, opioid-related drug treatment admissions, and opioid-related overdose deaths.

    Additional information regarding the association between cannabis and opioids is available from NORML’s fact-sheet here.

  • by Paul Armentano, NORML Deputy Director February 7, 2018

    Medical marijuanaCannabis therapy is safe and effective among elderly patients diagnosed with chronic pain, according to clinical data published online ahead of print in the European Journal of Internal Medicine.

    Researchers from Hebrew University and the Ben Gurion University of Negrev in Israel assessed the use of therapeutic cannabis over a period of six months in a cohort of 1,186 patients above 65 years of age. The majority of patients enrolled in the trial suffered from pain or cancer. Under an Israeli federal program, over 32,000 citizens are licensed to utilize cannabis therapy.

    “After six months of treatment, 93.7 percent of the respondents reported improvement in their condition, and the reported pain level was reduced from a median of 8 on a scale of 0-10 to a median of 4,” researchers reported. The majority of respondents also reported “a significant improvement in [their] overall quality of life.”

    Furthermore, over 18 percent of the study’s participants “stopped using opioid analgesics or reduced their dose” – a result that led investigators to conclude, “Cannabis can decrease the use of other prescription medicines, including opioids.” Numerous prior studies, such as those compiled here, similarly show that pain patients typically mitigate or eliminate their opioid use during cannabis therapy.

    The adverse effects most commonly reported by participants were dizziness and dry-mouth.

    Authors concluded: “The older population is a large and growing part of medical cannabis users. Our study finds that the therapeutic use of cannabis is safe and efficacious in this population.”

    Read the abstract of the study, “Epidemiological characteristics, safety and efficacy of medical cannabis in the elderly,” here.

  • by Paul Armentano, NORML Deputy Director November 20, 2017

    Pain reliefChronic pain patients enrolled in a statewide medical cannabis access program are significantly more likely to either reduce or cease their use of opioids as compared to non-enrolled patients suffering from similar pain conditions, according to data published online in the journal PLOS One.

    A team of investigators at the University of New Mexico assessed opioid prescription use patterns over a 21-month period in 37 pain patients enrolled in the state’s medicinal cannabis program versus 29 non-enrolled patients.

    Compared to non-users, medical cannabis enrollees “were more likely either to reduce daily opioid prescription dosages between the beginning and end of the sample period (83.8 percent versus 44.8 percent) or to cease filling opioid prescriptions altogether (40.5 percent versus 3.4 percent).” Enrollees were also more likely to report an improved quality of life.

    Authors concluded, “The clinically and statistically significant evidence of an association between MCP enrollment and opioid prescription cessation and reductions and improved quality of life warrants further investigations on cannabis as a potential alternative to prescription opioids for treating chronic pain.”

    Prior studies similarly report that patients enrolled in cannabis access programs are more likely to reduce their use of opioids and other prescription drugs.

    Full text of the study, “Association between medical cannabis and prescription opioid use in chronic pain patients: A preliminary cohort study,” appears online here. NORML’s marijuana and opioids fact-sheet is online here.

  • by Paul Armentano, NORML Deputy Director November 1, 2017

    GovChristieDespite the growing body of scientific evidence showing that cannabis access is associated with reductions in opioid use and mortality, the Chairman of the White House’s Commission on Combating Drug Addiction and the Opioid Crisis today called upon the President to reject any efforts to acknowledge marijuana’s promising role in mitigating opioid abuse and dependency.

    In a letter sent today to President Donald Trump by New Jersey Gov. Chris Christie, Chairman of the Committee, he writes:

    “The Commission acknowledges that there is an active movement to promote the use of
    marijuana as an alternative medication for chronic pain and as a treatment for opioid addiction. … There is a lack of sophisticated outcome data on dose, potency, and abuse potential for marijuana. This mirrors the lack of data in the 1990’s and early 2000’s when opioid prescribing multiplied across health care settings and led to the current
    epidemic of abuse, misuse and addiction. The Commission urges that the same mistake is not made with the uninformed rush to put another drug legally on the market in the midst of an overdose epidemic.”

    President Trump established the Commission in May via an executive order. Members of the Commission issued their policy recommendations today.

    In recent months, dozens of peer-reviewed studies have concluded that legal cannabis access is associated with reduced rates of opioid use, spending, abuse, hospitalization, and mortality. Summaries and links to these studies are available here.

    Despite over 10,000 advocates communicating this information to the Commission, members of the committee have chosen to disregard it. Moreover, Gov. Christie opines in today’s letter that cannabis exposure increases the likelihood that one will become opioid dependent — an allegation that was recently rejected by the National Academy of Sciences, which, in a January 2017 review of some 10,000 peer-reviewed studies, failed to identify even one “good or fair-quality systematic review that reported on the association between cannabis use and the initiation of use of opioids.”

    NORML thanks the thousands of you who took the time to try to inform and educate this Commission and regrets that its members continue to place political ideology above the health and safety of American lives.

Page 1 of 512345